Distinctions between dopamine transporter antagonists could be just around the bend

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 616-618

  Henry, L Keith ^a,c   Blakely, Randy D ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BENZATROPINE; COCAINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; RIMCAZOLE;

COCAINE DEPENDENCE; DRUG BINDING; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG USE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SUBSTANCE ABUSE; SUBSTITUTION THERAPY;

ANIMALS; BENZTROPINE; CARBAZOLES; COCAINE; DISCRIMINATION LEARNING; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOTOR ACTIVITY; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RATS;

EID: 40849140989     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.044586     Document Type: Short Survey

References (14)

1. Chen JG and Rudnick G (2000) Permeation and gating residues in serotonin transporter. Proc Natl Acad Sci U S A 97:1044-1049.
2. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, Quan N, Stephens RL, Hill ER, Nottoli T, et al. (2006) Abolished cocaine reward in mice with a cocainein-sensitive dopamine transporter. Proc Natl Acad Sci U S A 103:9333-9338
3. Dutta AK, Zhang S, Kolhatkar R and Reith ME (2003) Dopamine transporter as target for drug development of cocaine dependence medications. Eur J Pharmacol 479:93-106.
4. Gaffaney JD and Vaughan RA (2004) Uptake Inhibitors but not substrates induce protease resistance in extracellular loop two of the dopamine transporter. Mol Pharmacol 65:692-701.
5. Lin Z and Madras BK (2006) Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol (175):327-371.
6. Katz JL, Izenwasser S, Kline RH, Allen AC, and Newman AH (1999) Novel 3α-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine. J Pharmacol Exp Ther 288:302-315.
7. Katz JL, Libby TA, Kopajtic T, Husbands SM, and Newman AH (2003) Behavioral effects of rimcazole analogs alone and in combination with cocaine. Eur J Pharmacol 468:109-119.
8. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823.
9. Loland CJ, Granas C, Javitch JA, and Gether U (2004) Identification of intracellular residues in the dopamine transporter critical for regulation of transporter conformation and cocaine binding. J Biol Chem 279:3228-3238.
10. 2+ switch in the dopamine transporter: mutation of an intracellular tyrosine constitutively alters the conformational equilibrium of the transport cycle. Proc Natl Acad Sci U S A 99:1683-1688.
11. Mason JN, Deecher DC, Richmond RL, Stack G, Mahaney PE, Trybulski E, Winneker RC, and Blakely RD (2007) Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. J Pharmacol Exp Ther 323:720-729.
12. Pouletty P (2002) Drug addictions: towards socially accepted and medically treatable diseases. Nat Rev Drug Discov 1:731-736.
13. Volkow N and Li TK (2005) The neuroscience of addiction. Nat Neurosci 8:1429-1430.
14. --dependent neurotransmitter transporters. Nature 437:215-223